To compare the efficacy of three chemotherapeutic combinations for laparoscopic hyperthermic intraperitoneal perfusion chemotherapy (HIPPC) in the treatment of malignant ascites secondary to unresectable gastric cancer (GC).
Materials and Methods:
From January 2010 to December 2013, 38 GC patients were randomly divided into three groups and treated by laparoscopic HIPPC with one of the three following chemotherapy combinations: raltitrexed (Ra) with oxaliplatin [trans-(±)-diaminocyclohexane oxalatoplatinum (l-OHP)], Ra with cisplatin (DDP), and Ra with mitomycin C (MMC). Perioperative complications, patients' quality of life, and survival were recorded and compared among the three groups.
Results:
The intraoperative course was successful in all patients, and no perioperative death or complication related to laparoscopic HIPPC was documented. The median follow-up period was 9 months, and the median survival was 7.5 months for all patients. Patients in the Ra/l-OHP group had a median survival of 8.7 months, the Ra/DDP group had a median survival of 5.6 months, and the Ra/MMC group had a median survival of 7.5 months. Patients' median survival in the Ra/l-OHP group and Ra/MMC group was significantly longer than in the Ra/DDP group (P < .05). No significant difference was found in total remission rate of ascites, increase in the Karnofsky Performance Scale, and incidence rate of port-site metastases among the three groups.
Conclusions:
Laparoscopy-assisted HIPPC provides modest yet encouraging efficacy for malignant ascites secondary to disseminated GC. Our preliminary data indicate that the chemotherapeutic combination of Ra/l-OHP and Ra/MMC might be more beneficial compared with Ra/DDP in terms of patients' survival.
Get full access to this article
View all access options for this article.
References
1.
YangXJ, LiY, YonemuraY. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol, 2010; 101:457–464.
2.
MaeharaY, HasudaS, KogaT, TokunagaE, KakejiY, SugimachiK. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg, 2000; 87:353–357.
3.
ChenC, ChenLQ, ChenLD, YangGL, LiY. Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: Analysis of 100 cases. Hepatogastroenterology, 2008; 55:991–997.
4.
ZhangYH, LiY, ChenC, PengCW. Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: Study on 166 cases and suggestion for new therapy. Hepatogastroenterology, 2009; 56:1750–1754.
ChuDZ, LangNP, ThompsonC, OsteenPK, WestbrookKC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer, 1989; 63:364–367.
7.
YamadaS, TakedaT, MatsumotoK. Prognostic analysis of malignant pleural and peritoneal effusions. Cancer, 1983; 51:136–140.
8.
WoopenH, SehouliJ. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res, 2009; 29:3353–3359.
9.
BeckerG, GalandiD, BlumHE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer, 2006; 42:589–597.
SprattJS, AdcockRA, SherrillW, TravathenS. Hyperthermic peritoneal perfusion system in canines. Cancer Res, 1980; 40:253–255.
12.
SprattJS, AdcockRA, MuskovinM, SherrillW, McKeownJ. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980; 40:256–260.
13.
LevineEA, StewartJHT, RussellGB, GeisingerKR, LoggieBL, ShenP. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures. J Am Coll Surg, 2007; 204:943–953; discussion 953–945.
14.
BenoitL, CheynelN, Ortega-DeballonP, GiacomoGD, ChauffertB, RatP. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: A novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol, 2008; 15:542–546.
15.
KusamuraS, YounanR, BarattiD, CostanzoP, FavaroM, GavazziC, DeracoM. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer, 2006; 106:1144–1153.
16.
Al-ShammaaHA, LiY, YonemuraY. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol, 2008; 14:1159–1166.
17.
ScaringiS, KianmaneshR, SabateJM, FacchianoE, JouetP, CoffinB, ParmentierG, HayJM, FlamantY, MsikaS. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: A single Western center experience. Eur J Surg Oncol, 2008; 34:1246–1252.
18.
HallJJ, LoggieBW, ShenP, BeamerS, Douglas CaseL, McquellonR, GeisingerKR, LevineEA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg, 2004; 8:454–463.
19.
BozzettiF, YuW, BarattiD, KusamuraS, DeracoM. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol, 2008; 98:273–276.
20.
GlehenO, SchreiberV, CotteE, Sayag-BeaujardAC, OsinskyD, FreyerG, FrancoisY, VignalJ, GillyFN. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg, 2004; 139:20–26.
21.
KimJY, BaeHS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer, 2001; 4:27–33.
22.
MarrelliD, RovielloF, De ManzoniG, MorgagniP, Di LeoA, SaragoniL, De StefanoA, FolliS, CordianoC, PintoE. Different patterns of recurrence in gastric cancer depending on Lauren's histological type: Longitudinal study. World J Surg, 2002; 26:1160–1165.
23.
WuCW, LoSS, ShenKH, HsiehMC, ChenJH, ChiangJH, LinHJ, LiAF, LuiWY. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg, 2003; 27:153–158.
24.
FujimotoS, ShresthaRD, KokubunM, OhtaM, TakahashiM, KobayashiK, KiuchiS, OkuiK, MiyoshiT, ArimizuN, et al.Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg, 1988; 208:36–41.
25.
EliasD, LefevreJH, ChevalierJ, BrouquetA, MarchalF, ClasseJM, FerronG, GuilloitJM, MeeusP, GoereD, BonastreJ. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol, 2009; 27:681–685.
26.
AartsF, HendriksT, BoermanOC, KoppeMJ, OyenWJ, BleichrodtRP. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol, 2007; 14:3274–3282.
27.
ZanonC, BortoliniM, ChiappinoI, SimoneP, BrunoF, GagliaP, AiroldiM, DeriuL, MashiahA. Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg, 2006; 30:2025–2032.
28.
HuhJW, KimYJ, KimHR. Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis. World J Gastroenterol, 2009; 15:756–757.
29.
SmeenkRM, VerwaalVJ, ZoetmulderFA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—A report of 103 procedures. Eur J Surg Oncol, 2006; 32:186–190.
30.
DeracoM, BarattiD, IngleseMG, AllariaB, AndreolaS, GavazziC, KusamuraS. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol, 2004; 11:393–398.
31.
BryantJ, CleggAJ, SidhuMK, BrodinH, RoyleP, DavidsonP. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg, 2005; 92:153–158.
32.
MinerTJ, ShiaJ, JaquesDP, KlimstraDS, BrennanMF, CoitDG. Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy. Ann Surg, 2005; 241:300–308.
33.
HelmCW, BristowRE, KusamuraS, BarattiD, DeracoM. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol, 2008; 98:283–290.
34.
KnutsenA, SielaffTD, GreenoE, TuttleTM. Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg, 2006; 10:1038–1043.
35.
Gesson-PauteA, FerronG, ThomasF, De LaraEC, ChatelutE, QuerleuD. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): An experimental study. Ann Surg Oncol, 2008; 15:339–344.
36.
GarofaloA, ValleM, GarciaJ, SugarbakerPH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol, 2006; 32:682–685.
37.
FerronG, Gesson-PauteA, ClasseJM, QuerleuD. Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: An experimental study. Gynecol Oncol, 2005; 99:358–361.
38.
FacchianoE, ScaringiS, KianmaneshR, SabateJM, CastelB, FlamantY, CoffinB, MsikaS. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol, 2008; 34:154–158.
39.
BaMC, CuiSZ, LinSQ, TangYQ, WuYB, WangB, ZhangXL. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol, 2010; 16:1901–1907.
40.
Di GiorgioA, NaticchioniE, BiacchiD, SibioS, AccarpioF, RoccoM, TarquiniS, Di SeriM, CiardiA, MontruccoliD, SammartinoP. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 2008; 113:315–325.
41.
National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2010.
42.
SchoennemannKR, BjerregaardJK, HansenTP, De StrickerK, GjerstorffMF, JensenHA, VestermarkLW, PfeifferP. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer, 2011; 14:219–225.
